Gut Microbiota Market Share

  • Report ID: 3251
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Gut Microbiota Market Share

North American Market Forecast

North America industry is set to hold largest revenue share of 35% by 2037, The growth of the market can be attributed majorly to the rising concern about digestive illnesses such as gastroesophageal reflux disease (GERD) as well as other lifestyle disorders owing to the growing sedentary lifestyle, remote jobs, junk foods, and others. For instance, as per a study in 2022, nearly 20% of the U.S. population was affected by GERD or chronic acid reflux. Moreover, the rising spending on health care in the region is further expected to enhance the gut microbiota market in the region.

Europe Market Forecast

The European gut microbiota market is estimated to be the second largest, registering a share of about 25% by the end of 2037. The growth of the market can be attributed majorly to the rapidly rising geriatric population as well as the growing ubiquity of heart diseases and other chronic diseases coupled with the increasing research & development and clinical trials in the field of microbiome therapy in the region. It was found that over one-fifth or over 21% of the European Union population was aged 65 and over in 2022. Moreover, the increasing awareness of preventive healthcare in the region is further anticipated to propel regional market growth.

APAC Market Statistics

Further, the market in the Asia Pacific, amongst the market in all the other regions, is projected to hold a majority of the share by the end of 2037. The presence of a vast pool population as well as the growing prevalence of autoimmune diseases such as celiac diseases, diabetes, asthma, cancer, and others in the region coupled with the increasing prevalence of obesity and other lifestyle-related diseases. For instance, a study conducted in 2019, recruiting nearly 19,778 Chinese adolescents and young adults, showed that the prevalence of celiac disease autoimmunity reached nearly 2.19% in the country. Moreover, diabetes prevalence in Chinese adults is estimated to rise from 8% to around 9.5% among the age group of 20–79 years between 2020-2030.

Research Nester
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 3251
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of gut microbiota is estimated at USD 1.02 billion.

The gut microbiota market size was over USD 770.87 million in 2024 and is anticipated to cross USD 7.56 billion by 2037, growing at more than 19.2% CAGR during the forecast period i.e., between 2025-2037. The increasing focus on gut health and the immunity system post-pandemic as well as the rising prevalence of digestive illness coupled with chronic diseases will boost the market growth.

North America industry is set to hold largest revenue share of 35% by 2037, led by rising concern about digestive illnesses such as gastroesophageal reflux disease (GERD) as well as other lifestyle disorders.

The major players in the market are Merck KGaA, Metabiomics Corporation, ViThera Pharmaceuticals, Inc., Second Genome Inc., Microbiome Therapeutics LLC, Vedanta Biosciences, Inc., Osel, Inc., Synthetic Biologics, Inc., Synlogic, 4D Pharma plc, Metabogen AB, Symbiotix Biotherapies, Inc.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample